Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

RNA viruses cause animal, human, and zoonotic diseases that affect millions of individuals, as is being exemplified by the devastating ongoing epidemic of the recently identified SARS-Cov-2. For years vaccines have had an enormous impact on overcoming the global burden of diseases. Nowadays, a vast number of different approaches, from purified inactivated and live attenuated viruses, nucleic acid (DNA or RNA) based candidates, virus-like particles, subunit elements, and recombinant viruses are been employed to combat viruses. However, for many of them efficient vaccines are not yet available. This will probably change dramatically with the current Covid-19 pandemic, as a vast variety of vaccinology approaches are being tested against it, with hundreds of candidates under development, dozens of them already in clinical trials, a fact that is breaking records in vaccine development and implementation. This is becoming possible thanks to the enormous work carried out during years to have the bases for a quick response, even against unknown pathogens, in an impressive short time. Here, results obtained with different vaccine´s methodological approaches against human (HIV, HCV, HRV) animal (PRRSV, PEDV, FMDV, VHSV) and zoonotic (RVF, WNV), RNA viruses are presented by field experts.

Medicine --- artificial protein --- polyepitope B- and T-cell HIV-1 immunogen --- epitopes of broadly neutralizing HIV-1 antibodies --- peptide mimic of discontinuous epitope --- immunogenicity --- birds --- vaccines --- West Nile virus --- flavivirus --- herd immunity --- porcine epidemic diarrhea virus --- RNA interference --- processivity factor --- intestine epithelial cells --- N gene --- rotavirus nanoparticle vaccine --- gnotobiotic pigs --- FMDV --- peptide vaccine --- single dose --- amount --- pig --- VHSV --- non-virion (NV) --- transcriptome profiling --- rainbow trout --- immune pathways --- Rift Valley fever virus (RVFV) --- modified vaccinia Ankara (MVA) --- cellular response --- neutralizing antibodies --- Gn Gc glycoproteins --- passive serum:virus transfer --- hepatitis C virus --- neutralising antibodies --- animal models --- immune responses --- PRRSV Mosaic T-cell DNA vaccine VACV --- PRRS --- cross protection --- heterologous virus challenge --- artificial protein --- polyepitope B- and T-cell HIV-1 immunogen --- epitopes of broadly neutralizing HIV-1 antibodies --- peptide mimic of discontinuous epitope --- immunogenicity --- birds --- vaccines --- West Nile virus --- flavivirus --- herd immunity --- porcine epidemic diarrhea virus --- RNA interference --- processivity factor --- intestine epithelial cells --- N gene --- rotavirus nanoparticle vaccine --- gnotobiotic pigs --- FMDV --- peptide vaccine --- single dose --- amount --- pig --- VHSV --- non-virion (NV) --- transcriptome profiling --- rainbow trout --- immune pathways --- Rift Valley fever virus (RVFV) --- modified vaccinia Ankara (MVA) --- cellular response --- neutralizing antibodies --- Gn Gc glycoproteins --- passive serum:virus transfer --- hepatitis C virus --- neutralising antibodies --- animal models --- immune responses --- PRRSV Mosaic T-cell DNA vaccine VACV --- PRRS --- cross protection --- heterologous virus challenge